All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @antrasena7 on TikTok · 85s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @antrasena7's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Mka Nam 2 Ju Ju, Ato Ibu Tamore.
  2. 0:02MK-677, MK-677, MK-677.
  3. 0:10I'm not sure if Mka Nam 2 Ju Ju Ju, I'm not sure if Mka Nam 2.
  4. 0:14Mka Inila Grote Hormone's Secret Go.
  5. 0:17I'm not sure if Mka Nam 2.
  6. 0:18I'm not sure if Mka Nam 2.
  7. 0:20I'm not sure if Mka Nam 2.
  8. 0:22I'm not sure if Mka Nam 2.
  9. 0:25Mk Jadi, I feel like I'm running yet,
  10. 0:29I'm not now going to get each one
  11. 0:31but I'm not
  12. 0:36eeeeeean
  13. 0:37and I'll see that everyone can work there and speak F
  14. 1:23I like to take a load of that.

MK-677 side effects on TikTok: what the studies actually say

antrasena7

TikTok creator

23.8K viewsWatch on TikTok

Quick answer

MK-677 (ibutamoren) is an orally active ghrelin receptor agonist that stimulates GH and IGF-1 secretion. The two side effects described in the caption, increased appetite via ghrelin mimicry and mild edema via IGF-1-mediated sodium retention, are supported by clinical trial data. However, the most clinically significant risk documented in controlled trials is worsening of insulin sensitivity, which the video does not mention.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 9 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For MK-677 side effects on TikTok: what the studies actually say, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

MK-677 side effects on TikTok: what the studies actually say is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "MK-677 side effects on TikTok: what the studies actually say" from antrasena7. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: MK-677 (ibutamoren) is an orally active ghrelin receptor agonist that stimulates GH and IGF-1 secretion.

The reason this review is not generic is the source wording and the canonical claim label "peptides side effect mk 677 yang paling sering 1 nafsu makan meningka." In this clip, the useful excerpt is: "Mka Nam 2 Ju Ju, Ato Ibu Tamore." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Ipamorelin, the first selective growth hormone secretagogue (1998), The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation (2001), and Influence of chronic treatment with the growth hormone secretagogue Ipamorelin (2002), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Mild peripheral edema is a real and common side effect, reported as dose-dependent in Svensson et al.
People who land here are usually trying to understand whether the Peptide social video fact-checks claim is evidence-backed, safe, and relevant to their own situation.
The strongest next step is to compare the claim with FormBlends' Peptide social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

MK-677 (ibutamoren) is an orally active ghrelin receptor agonist that stimulates GH and IGF-1 secretion.

FormBlends verdict

Peptide social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • MK-677 (ibutamoren) is an orally active ghrelin receptor agonist that stimulates GH and IGF-1 secretion. The two side effects described in the caption, increased appetite via ghrelin mimicry and mild edema via IGF-1-mediated sodium retention, are supported by clinical trial data. However, the most clinically significant risk documented in controlled trials is worsening of insulin sensitivity, which the video does not mention.
  • MK-677 is a ghrelin receptor agonist, not a peptide, and its appetite-stimulating effect via GHSR-1a is one of the best-documented pharmacological actions in the clinical literature.
  • Mild peripheral edema is a real and common side effect, reported as dose-dependent in Svensson et al. (1998), and is mechanistically linked to GH and IGF-1 effects on renal sodium handling.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • MK-677 is a ghrelin receptor agonist, not a peptide, and its appetite-stimulating effect via GHSR-1a is one of the best-documented pharmacological actions in the clinical literature.
  • Mild peripheral edema is a real and common side effect, reported as dose-dependent in Svensson et al. (1998), and is mechanistically linked to GH and IGF-1 effects on renal sodium handling.
  • The video omits the most serious documented risk: a two-year RCT by Nass et al. (2008, Annals of Internal Medicine) found MK-677 significantly increased fasting glucose and HbA1c, raising meaningful concerns for metabolic health.
  • MK-677 is not approved by the FDA or EMA for any therapeutic use outside of clinical trials, meaning all current human use outside of research settings is unregulated.
  • Without lab monitoring of IGF-1 levels, users have no way to verify whether their levels are within a physiologically safe range, making self-directed use a genuine blind spot.
  • Distinguishing water retention from actual fat gain without body composition testing is difficult in practice, and the clean framing in the caption may give users false reassurance about physical changes they observe.
  • Anyone with prediabetes, insulin resistance, metabolic syndrome, or a family history of type 2 diabetes faces a categorically different risk profile with MK-677 than what general social media content typically addresses.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @antrasena7 actually say?

The transcript from this video is largely incoherent, which makes direct quoting impossible for most of it. What we can work with is the written caption, which claims MK-677's two most common side effects are increased appetite and water retention. The creator attributes the hunger effect to ghrelin and the water retention to elevated IGF-1, and specifies that the swelling is "bukan lemak, tapi cairan" (not fat, but fluid). These are the actual checkable claims here. The verbal content of the video, based on the transcript provided, does not yield coherent statements worth analyzing.

So we are fact-checking the caption, not the spoken content. That is worth being transparent about up front.

Does the science back this up?

On the hunger side, yes, the mechanism is real. MK-677 is a ghrelin mimetic, meaning it binds to the ghrelin receptor (GHSR-1a) and stimulates growth hormone secretion. Ghrelin is well-established as an orexigenic hormone. Increased appetite is one of the most consistently reported effects in the clinical literature. Chapman et al. (1996, Journal of Clinical Endocrinology and Metabolism) documented significant increases in appetite in their early dose-escalation work with MK-677 in healthy adults.

Water retention is also real and mechanistically plausible. IGF-1 promotes sodium and water reabsorption in the kidneys. When MK-677 raises GH and downstream IGF-1, mild edema, particularly in the extremities, is a predictable result. Svensson et al. (1998, Journal of Clinical Endocrinology and Metabolism) reported edema as a dose-dependent side effect in studies with MK-677 in adults with GH deficiency. The "not fat, but fluid" distinction is technically correct, though it is worth noting that distinguishing the two subjectively is harder than the caption implies.

What did they get wrong (or right)?

Credit where it is due: the two side effects listed are genuinely the most commonly reported in trials, and the mechanistic explanations are directionally accurate. Most content about MK-677 on social media either ignores side effects entirely or dramatically overstates benefits, so naming the downsides is a reasonable move.

What is missing, and this is a significant omission, is any mention of the more serious risks. MK-677 has been shown to worsen insulin sensitivity. Nass et al. (2008, Annals of Internal Medicine) found that two years of MK-677 use in older adults significantly increased fasting glucose and HbA1c levels. For anyone with prediabetes or metabolic syndrome, this is not a footnote. It is arguably the most clinically relevant risk.

The caption also frames these effects as manageable inconveniences without noting that MK-677 is not approved by any major regulatory body for human use outside of clinical trials. Presenting it as a clean compound with two mild, easily explained side effects is, at best, incomplete framing.

What should you actually know?

MK-677 has real pharmacological activity. It raises GH and IGF-1 measurably, which is why it has attracted research attention in sarcopenia, GH deficiency, and catabolic conditions. But "pharmacologically active" also means it carries real risks that go beyond bloating and hunger.

The insulin resistance signal from the literature is not subtle. The two-year RCT by Nass et al. is the longest controlled human trial available, and the glucose findings should be part of any honest conversation about this compound. People with family histories of diabetes, anyone already managing blood sugar, or individuals who are overweight are in a different risk category than a lean, healthy young adult.

Water retention may also be a proxy for IGF-1 levels running higher than intended. Without lab monitoring, users have no way to know where their IGF-1 actually lands. Chronically elevated IGF-1 has associations with certain cancer risks in epidemiological literature, though causality from supplementation specifically has not been established.

MK-677 is also not a legally approved therapeutic in most countries. Sourcing, purity, and dosing accuracy outside of a supervised clinical context are genuine variables that no amount of TikTok education resolves.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

antrasena7 · TikTok creator

23.8K views on this video

Side effect MK-677 yang paling sering 1️⃣ Nafsu makan meningkat Efek paling umum Terjadi karena MK-677 memengaruhi hormon ghrelin (hormon lapar) 2️⃣ Retensi air (badan terasa “berair”) Bisa muncul bengkak ringan di: tangan kaki wajah Biasanya karena peningkatan IGF-1 Bukan lemak, tapi cairan --- 3️⃣ Mengantuk & lemas Beberapa orang merasa: ngantuk berlebihan badan terasa berat Efek ini sering muncul di awal penggunaan --- 4️⃣ Gula darah bisa naik MK-677 dapat menurunkan sensitivitas insu

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about mk-677?

MK-677 is a ghrelin receptor agonist, not a peptide, and its appetite-stimulating effect via GHSR-1a is one of the best-documented pharmacological actions in the clinical literature.

What does the video say about mild peripheral edema?

Mild peripheral edema is a real and common side effect, reported as dose-dependent in Svensson et al. (1998), and is mechanistically linked to GH and IGF-1 effects on renal sodium handling.

What does the video say about the video omits the most serious documented risk: a two-year?

The video omits the most serious documented risk: a two-year RCT by Nass et al. (2008, Annals of Internal Medicine) found MK-677 significantly increased fasting glucose and HbA1c, raising meaningful concerns for metabolic health.

What does the video say about mk-677?

MK-677 is not approved by the FDA or EMA for any therapeutic use outside of clinical trials, meaning all current human use outside of research settings is unregulated.

What does the video say about without lab monitoring of igf-1 levels, users have no way?

Without lab monitoring of IGF-1 levels, users have no way to verify whether their levels are within a physiologically safe range, making self-directed use a genuine blind spot.

What does the video say about distinguishing water retention from actual fat gain without body composition?

Distinguishing water retention from actual fat gain without body composition testing is difficult in practice, and the clean framing in the caption may give users false reassurance about physical changes they observe.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by antrasena7, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.